Key result
Cardiomyocytes expressing the BAG3C151R variant demonstrated improved response to proteotoxic stress in an allele dose-dependent manner compared to wild-type cells.
Why the study?
A common allelic block linked to BAG3 is associated with decreased incidence of heart failure, but the underlying molecular mechanism for this protection remains elusive.
p-value: p=<0.0001
The BAG3 C151R variant enhances cardiomyocyte resistance to proteotoxic stress by altering protein interactions to favor myofibrillar integrity, offering a mechanistic explanation for its association with reduced heart failure risk.
Multiple genetic association studies have correlated a common allelic block linked to the BAG3 gene with a decreased incidence of heart failure, but the molecular mechanism for such protection remains elusive. One of the variants in this allele block is coding, changing cysteine to arginine at position 151 of BAG3 (rs2234962-BAG3 C151R ). Here, we use induced pluripotent stem cells (iPSC) to test if the BAG3 C151R variant alters protein and cellular function in human cardiac myocytes. Quantitative protein interaction network analysis identified specific changes in BAG3 C151R protein interaction partners in cardiomyocytes but not in iPSCs or an immortalized cell line. Knockdown of BAG3 interacting factors in cardiomyocytes followed by myofibrillar analysis revealed that BAG3 C151R associates more strongly with proteins involved in the maintenance of myofibrillar integrity. Finally, we demonstrate that cardiomyocytes expressing the BAG3 C151R variant have improved response to proteotoxic stress in an allele dose-dependent manner. This study suggests that the BAG3 C151R variant increases cardiomyocyte protection from stress by enhancing the recruitment of factors critical to the maintenance of myofibril integrity, hinting that this variant could be responsible for the cardioprotective effect of the haplotype block. By revealing specific changes in preferential binding partners of the BAG3 C151R protein variant, we also identify potential targets for the development of novel cardioprotective therapies.
No takes yet. Share an insight, caveat, or question.
Pérez-Bermejo et al. (2021) studied Heart failure (in vitro model). BAG3C151R variant vs. BAG3WT (wild-type) was evaluated on Resistance to proteotoxic stress (bortezomib EC50) (p=<0.0001). Cardiomyocytes expressing the BAG3C151R variant demonstrated improved response to proteotoxic stress in an allele dose-dependent manner compared to wild-type cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: